2006
A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin's Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy.
Longo D, Glatstein E, Duffey P, Young R, Fiem S, Jaffe E, Camphausen K, Wilson W, DeVita V. A Prospective Trial of Radiation Alone vs Combination Chemotherapy Alone for Early-Stage Hodgkin's Disease: Implications of 25-Year Follow-Up to Current Combined Modality Therapy. Blood 2006, 108: 98. DOI: 10.1182/blood.v108.11.98.98.Peer-Reviewed Original ResearchStage IA diseaseDisease-free survivalComplete responseModality therapyHodgkin's diseaseRadiation therapyMOPP chemotherapyFirst remissionIA diseaseOverall survivalSecond cancersSignificant treatment toxicityStage Hodgkin's diseaseCombined modality therapyRadiation-treated patientsIIIA Hodgkin's diseaseAdministration of radiationInitial remissionProspective trialTreatment toxicityCombination chemotherapyIA patientsLate effectsPatientsMOPP
1997
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo D, Glatstein E, Duffey P, Young R, Ihde D, Bastian A, Wilson W, Wittes R, Jaffe E, Hubbard S, DeVita V. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Journal Of Clinical Oncology 1997, 15: 3338-46. PMID: 9363863, DOI: 10.1200/jco.1997.15.11.3338.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedPrednisoneProcarbazineProspective StudiesTreatment OutcomeVinblastineVincristineConceptsMantle field radiation therapyDisease-free survivalLarge mediastinal massMediastinal Hodgkin's diseaseHodgkin's diseaseABVD chemotherapyRadiation therapyOverall survivalMediastinal massMOPP/ABVDSecond solid tumorsTreatment-related pneumonitisComplete response rateAnn Arbor stageClinical prognostic factorsErythrocyte sedimentation rateTreatment of patientsAge 35 yearsLactate dehydrogenase levelsABVD therapyDacarbazine (ABVD) chemotherapyMedian followMOPP chemotherapySalvage therapyB symptoms
1991
Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Longo D, Russo A, Duffey P, Hubbard S, Glatstein E, Hill J, Jaffe E, Young R, DeVita V. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal Of Clinical Oncology 1991, 9: 227-35. PMID: 1988570, DOI: 10.1200/jco.1991.9.2.227.Peer-Reviewed Original ResearchConceptsMediastinal Hodgkin's diseaseDisease-free survivalComplete respondersModality treatmentHodgkin's diseaseNational Cancer InstituteComplete remissionRadiation therapyMantle radiation therapyStage IIB diseaseOverall survival differenceMOPP chemotherapyDurable remissionsIIB diseaseLate complicationsModality therapyOverall survivalComplete responseMediastinal massSubsequent therapyTumor mortalitySurvival differencesChest radiographsRetrospective analysisMaximal response
1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphoma
1981
Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease
Schilsky R, Sherins R, Hubbard S, Wesley M, Young R, DeVita V. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. The American Journal Of Medicine 1981, 71: 552-556. PMID: 7282743, DOI: 10.1016/0002-9343(81)90205-9.Peer-Reviewed Original ResearchConceptsOvarian failureMOPP chemotherapyOvarian functionChemotherapy-induced ovarian failureAge 25Causes of amenorrheaCompletion of chemotherapyPercent of patientsLong-term followTime of evaluationTime of treatmentPersistent amenorrheaChemotherapy regimenOlder patientsMedian ageHodgkin's diseaseEstradiol levelsSerum gonadotropinPatientsAmenorrheaChemotherapyNormal childrenWomenDiseaseTreatment
1980
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease.
Fisher R, DeVita V, Bostick F, Vanhaelen C, Howser D, Hubbard S, Young R. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Annals Of Internal Medicine 1980, 92: 595-9. PMID: 6992672, DOI: 10.7326/0003-4819-92-5-595.Peer-Reviewed Original ResearchConceptsLong-term survivorsMitogen-induced lymphocyte proliferationPersistent immunologic abnormalitiesHodgkin's diseaseImmunologic abnormalitiesE rosettesLymphocyte proliferationAdvanced diffuse histiocytic lymphomaDepressed cellular immunityAdvanced Hodgkin's diseaseDisease-free intervalDiffuse histiocytic lymphomaB cell numbersNormal control subjectsComparable chemotherapyMOPP chemotherapyUntreated patientsCellular immunityControl subjectsHistiocytic lymphomaImmunologic studiesNormal rangeControl populationChemotherapyAbnormalities
1979
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.
Fisher R, DeVita V, Hubbard S, Simon R, Young R. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Annals Of Internal Medicine 1979, 90: 761-3. PMID: 434676, DOI: 10.7326/0003-4819-90-5-761.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseProlonged disease-free survivalDisease-free survivalLong-term survivalMOPP chemotherapyMOPP therapyComplete remissionMedian survivalMedian durationRe-treatmentMOPPRemissionHodgkinPatientsRelapseReinductionNitrogen mustardMonthsSurvivalDiseasePrednisoneDurationProcarbazineChemotherapyVincristine
1975
In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas.
Bull J, DeVita V, Carbone P. In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas. Blood 1975, 45: 833-42. PMID: 1125431, DOI: 10.1182/blood.v45.6.833.bloodjournal456833.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseMixed lymphomaUntreated patientsHistiocytic-lymphocytic lymphomasAdvanced Hodgkin's diseaseMOPP chemotherapyGranulocyte colony formationCombination chemotherapyMarrow culturesCFU-CIn vitro examinationLymphomaChemotherapyGranulocyte productionPatientsLong-term effectsAcute responseHodgkinColony formationDecreased numberDiseaseColony growthIn Vitro Granulocyte Production in Patients With Hodgkin’s Disease and Lymphocytic, Histiocytic, and Mixed Lymphomas
Bull J, DeVita V, Carbone P. In Vitro Granulocyte Production in Patients With Hodgkin’s Disease and Lymphocytic, Histiocytic, and Mixed Lymphomas. Blood 1975, 45: 833-842. DOI: 10.1182/blood.v45.6.833.833.Peer-Reviewed Original ResearchHodgkin's diseaseMixed lymphomaUntreated patientsHistiocytic-lymphocytic lymphomasAdvanced Hodgkin's diseaseMOPP chemotherapyGranulocyte colony formationCombination chemotherapyMarrow culturesCFU-CIn vitro examinationLymphomaChemotherapyGranulocyte productionPatientsLong-term effectsAcute responseHodgkinColony formationDecreased numberDiseaseColony growthResults of combination chemotherapy of non-Hodgkin's lymphoma.
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Results of combination chemotherapy of non-Hodgkin's lymphoma. British Journal Of Cancer. Supplement 1975, 2: 465-73. PMID: 1101932, PMCID: PMC2149606.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's lymphomaCombination chemotherapyHistological subgroupsLymphocytic lymphomaMonths of treatmentDiffuse histiocytic lymphomaMOPP chemotherapyMedian durationLate recurrenceLymph nodesNodular histologyHistiocytic lymphomaRemissionExtended survivalBone marrowClinical validityLymphomaAdvanced stageChemotherapyPatientsRelapseInitial siteMonthsSurvival
1974
Potential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Potential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma. Blood 1974, 43: 181-189. PMID: 4589318, DOI: 10.1182/blood.v43.2.181.181.Peer-Reviewed Original ResearchConceptsComplete remissionMedian survivalCombination chemotherapyHodgkin's lymphomaExtended disease-free survivalDisease-free survivalImproved median survivalNon-Hodgkin lymphomaMOPP chemotherapyMedian durationFurther therapyNodular histologyHistologic subgroupsDiffuse histologyHistologic categoriesNodular patternAggressive subgroupClinical validityLymphomaAdvanced stageRemissionChemotherapyEntire groupPatientsSignificant differences